Literature DB >> 8249971

Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori.

W L Peterson1, C C Barnett, D J Evans, M Feldman, T Carmody, C Richardson, J Walsh, D Y Graham.   

Abstract

OBJECTIVES: To compare gastric secretory function in patients with duodenal ulcer and in healthy volunteers with and without Helicobacter pylori infection.
METHODS: Basal acid output, peak acid output, meal-stimulated acid output, fasting and meal-stimulated serum gastrin concentrations were measured in 136 healthy volunteers (63 H. pylori positive, 73 H. pylori negative) and 52 duodenal ulcer patients, all but one of whom were H. pylori positive.
RESULTS: By multivariate linear regression analysis, H. pylori infection was a significant negative predictor of basal acid output and a positive predictor of fasting and meal-stimulated gastrin concentrations. When compared to truly normal (i.e., H. pylori-negative) control subjects, duodenal ulcer patients had elevated basal acid output, peak acid output, fasting and meal-stimulated gastrin concentrations.
CONCLUSIONS: Our results show that in patients with duodenal ulcer disease, hypergastrinemia is largely related to gastric H. pylori infection, whereas acid hypersecretion is due to factors other than H. pylori.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8249971

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  20 in total

1.  Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors?

Authors:  E S Bonapace; R S Fisher; H P Parkman
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

2.  Mechanisms involved in Helicobacter pylori induced duodenal ulcer disease:an overview.

Authors:  Lars Olbe; Lars Fandriks; Annika Hamlet; Ann-Mari Svennerholm; Ann-Catrin Thoreson
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

3.  Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.

Authors:  A B R Thomson; M Keelan; R Lastiwka; S Appelman-Eszczuk; L Zuk; L Drozdowski; A Prentice; P Sinclair
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

Review 4.  Formulary management of antiulcer drugs: clinical considerations.

Authors:  S L Sankey; L S Friedman
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

5.  Distinct effects of tetragastrin in rat gastroduodenal mucosa on mucin content and mucosal protective action against histamine-induced injury.

Authors:  Y Komuro; K Ishihara; Y Kojima; K Saigenji; K Hotta
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

6.  H. pylori-negative duodenal ulcer prevalence and causes in 774 patients.

Authors:  J P Gisbert; M Blanco; J M Mateos; L Fernández-Salazar; M Fernández-Bermejo; J Cantero; J M Pajares
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

7.  Helicobacter pylori infection increases the risk of colorectal adenoma and adenocarcinoma, especially in women.

Authors:  Shunji Fujimori; Teruyuki Kishida; Tsuyoshi Kobayashi; Yoshihisa Sekita; Tsuguhiko Seo; Kazuhiro Nagata; Atsushi Tatsuguchi; Katya Gudis; Kimiyoshi Yokoi; Noritake Tanaka; Kiyohiko Yamashita; Takashi Tajiri; Yoshiharu Ohaki; Choitsu Sakamoto
Journal:  J Gastroenterol       Date:  2005-09       Impact factor: 7.527

8.  Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance.

Authors:  T Jaworski; I Sarosiek; S Sostarich; K Roeser; M Connor; S Brotze; G Wallner; J Sarosiek
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

9.  Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders.

Authors:  T Skoczylas; I Sarosiek; S Sostarich; C McElhinney; S Durham; J Sarosiek
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

10.  Treatment of Helicobacter gastritis with IL-4 requires somatostatin.

Authors:  Yana Zavros; Sivaprakash Rathinavelu; John Y Kao; Andrea Todisco; John Del Valle; Joel V Weinstock; Malcolm J Low; Juanita L Merchant
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.